Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Targeted Pharmacovigilance

The legacy of general health and science information has long provided a foundation for understanding broad physiological principles and disease prevention. Within this context, public health communications have historically emphasized risk factors such as lifestyle, genetics, and environmental exposures. As scientific inquiry deepens, the focus naturally narrows from population-level guidance to specific clinical scenarios where therapeutic interventions intersect with adverse outcomes. One such area involves the long-term use of bisphosphonate medications, originally developed to manage bone density disorders. Over time, clinical observations have identified a potential association between these agents and rare but serious conditions affecting the jaw. This shift from general health education to targeted pharmacovigilance reflects a broader evolution in medical discourse—moving from abstract wellness advice to concrete risk assessment in therapeutic settings. The transition now requires examining how occupational or clinical exposure contexts may influence the manifestation of such complications. By bridging the gap between general health literacy and specialized clinical evidence review, we can better appreciate how historical frameworks of disease causation inform current investigations into medication-related adverse events. This progression underscores the importance of adapting legacy knowledge to emerging questions about specific exposures and their potential consequences.

Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but the drug has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves necrotic bone exposure in the maxillofacial region, often presenting with pain, swelling, infection, and delayed healing after dental procedures. Clinical presentation and diagnosis of ONJ typically involve exposed necrotic bone in the jaw that persists for more than eight weeks, with or without associated symptoms such as pain, purulent discharge, or fistula formation. Diagnosis is primarily clinical, supported by imaging findings of bone destruction or sequestrum formation. The condition can occur spontaneously but is generally associated with tooth extraction, local infection, or trauma (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Multiscale characterization of jawbone tissue has provided insights into the unique responses of the jaw to bisphosphonate therapy, helping to understand the pathophysiology of bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanisms and Risk Factors for Fosamax-Associated ONJ

The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. While this mechanism is beneficial for osteoporosis, it may impair the normal remodeling and repair processes in the jawbone, particularly after dental procedures. The drug accumulates in bone tissue over time, and its long half-life contributes to prolonged suppression of bone turnover. Mechanistic pathways linking Fosamax to ONJ include inhibition of osteoclast activity, reduced angiogenesis, and altered immune responses. These effects can lead to compromised bone healing and increased susceptibility to infection and necrosis, especially in the jaw, which has high bone turnover and is frequently subjected to mechanical stress and microbial exposure. Risk factors for developing ONJ while taking Fosamax include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Temporal Relationship and Causation Considerations

The timeline between exposure to Fosamax and documented harm varies widely. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experienced relief of symptoms after stopping the medication, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that not all jaw symptoms are attributable to the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients require careful evaluation of individual risk factors and temporal relationships. The presence of known risk factors, such as recent dental procedures or concomitant medications, strengthens the association. However, ONJ can occur spontaneously in patients taking bisphosphonates, and the drug's labeling acknowledges this possibility (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information, which includes a dedicated section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings describe the condition, associated risk factors, and recommendations for management, including discontinuation of treatment before invasive dental procedures.

Summary of Clinical Evidence

In summary, the clinical evidence supports a causal link between Fosamax use and osteonecrosis of the jaw, particularly in the presence of known risk factors. The onset of symptoms can occur shortly after initiation or after months of use, and the risk increases with longer exposure. Patients and healthcare providers should be aware of these risks and consider preventive measures, such as dental evaluations before starting therapy and careful monitoring during treatment.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it related to osteonecrosis of the jaw?

Fosamax (alendronate sodium) is a bisphosphonate used to treat osteoporosis and other bone conditions. It has been associated with osteonecrosis of the jaw (ONJ), a condition involving necrotic bone exposure in the jaw, often after dental procedures. Clinical evidence supports a causal link, especially with longer use and presence of risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, or infection. Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How soon after starting Fosamax can ONJ occur?

The time to onset of symptoms can range from one day to several months after starting the drug. Most patients improve after stopping the medication, but some may experience recurrence if rechallenged (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.